ArticleEndocrine connections2025
Circular RNAs in diabetes mellitus and its complications: a systematic review and in silico analyses.
Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- circRNA_013145‑miR‑185‑5p‑RhoA axis: A novel mechanism in the pathophysiology of diabetes‑induced erectile dysfunction.International journal of molecular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Circular RNAs (circRNAs) have garnered attention as potential biomarkers for diabetes mellitus (DM) and its complications due to their stability and presence in various tissues and plasma. The objective of this study was to perform a systematic review of the available literature to better understand the involvement of circRNAs in DM and its chronic complications. Methods: PubMed and Embase repositories were searched to identify all studies that evaluated the expression of one or more circRNAs in samples from individuals with DM and without DM. Studies comparing circRNA expression between DM patients with or without chronic complications were also included. Results: In total, 2990 articles were found in the databases and, after excluding articles that did not meet the eligibility criteria, 130 articles were included in this systematic review. In these 130 studies, we identified over 3000 circRNAs differentially expressed between cases and controls. Among these, eight circRNAs were reported as altered in samples from three or more studies, which were selected for additional evaluations. Five of them were consistently dysregulated between DM patients and controls. The circRNAs hsa_circ_0000324 and hsa_circ_0060450 were increased, while the hsa_cic_0080325 was decreased in type 1 DM patients vs. controls. Moreover, hsa_circ_0054633 was increased in type 2 DM patients vs. controls, and hsa_circ_0003218 was decreased in gestational DM patients vs. controls. Regarding chronic DM complications, three circRNAs were identified as dysregulated: hsa_circ_0037128 and hsa_circ_0003928 in diabetic kidney disease and hsa_circ_0006057 in diabetic retinopathy. Conclusion: Eight circRNAs are dysregulated in DM and its chronic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.